Evidence map›Paper›PMID 25501824›Full record

ArticleCell death & disease2014

Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells.

Z Wang, X Shi, Y Li, J Fan, X Zeng, Z Xian, Z Wang, Y Sun, S Wang, P Song and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Z Wang1] Department of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China [2] Department of Biopharmaceutical Research, Shanghai Institute of Pharmaceutical Industry, Shanghai, China.
X ShiDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
Y LiDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
J FanDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
X ZengDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
Z XianDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
Z WangDepartment of Pulmonary Medicine, People's Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Y SunDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
S WangDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
P SongDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
S ZhaoDepartment of Head and Neck Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China.
H HuDepartment of Biopharmaceutical Research, Shanghai Institute of Pharmaceutical Industry, Shanghai, China.
D JuDepartment of Biosynthesis and Key Lab of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
Fudan University · CNSecond Military Medical University · CNShanghai Institute of Pharmaceutical Industry · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depletion of arginine by recombinant human arginase (rhArg) has proven to be an effective cancer therapeutic approach for a variety of malignant tumors. Triple-negative breast cancers (TNBCs) lack of specific therapeutic targets, resulting in poor prognosis and limited therapeutic efficacy. To explore new therapeutic approaches for TNBC we studied the cytotoxicity of rhArg in five TNBC cells. We found that rhArg could inhibit cell growth in these five TNBC cells. Intriguingly, accumulation of autophagosomes and autophagic flux was observed in rhArg-treated MDA-MB-231 cells. Inhibition of autophagy by chloroquine (CQ), 3-methyladenine (3-MA) and siRNA targeting Beclin1 significantly enhanced rhArg-induced cytotoxic effect, indicating the cytoprotective role of autophagy in rhArg-induced cell death. In addition, N-acetyl-l-cysteine (NAC), a common antioxidant, blocked autophagy induced by rhArg, suggesting that reactive oxygen species (ROS) had an essential role in the cytotoxicity of rhArg. This study provides new insights into the molecular mechanism of autophagy involved in rhArg-induced cytotoxicity in TNBC cells. Meanwhile, our results revealed that rhArg, either alone or in combination with autophagic inhibitors, might be a potential novel therapy for the treatment of TNBC.Cell Death and Disease (2014) 5, e1563; doi:10.1038/cddis.2014.503; published online 11 December 2014.

Indexed as

AutophagyApoptosisArginaseArginineCell Line, TumorCell ProliferationHumansTriple Negative Breast NeoplasmsArginaseArginine

Identifiers

PMID25501824
PMCPMC4454157
OpenAlexW2069033411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.